Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check4 days agoChange DetectedAdded Hurthle cell carcinoma of thyroid and differentiated thyroid carcinoma to the conditions, and included a Resources section with the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No user-facing content or functionality is affected.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a metadata version change and does not modify core content such as study details or eligibility criteria.SummaryDifference0.0%

- Check54 days agoChange DetectedSite footer updated to Revision: v3.4.2; the government funding-lapse notice and the older Revision: v3.4.1 label were removed.SummaryDifference0.4%

- Check61 days agoChange DetectedA site-wide notice about a lapse in government funding was added, and the page shows a new revision tag (v3.4.1) replacing the previous (v3.4.0).SummaryDifference0.4%

- Check69 days agoChange DetectedAdded UI elements for glossary visibility and new metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted, Revision: v3.4.0). Removed older metadata labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.